Orthogate Subspecialty Journal Scan: Knee Arthroplasty & Reconstruction

Curated critical appraisals of recent high-impact trials and clinical evidence across knee arthroplasty and joint preservation, evaluating indwelling adductor canal pain catheters versus single-shot blocks in TKA, intrawound vancomycin powder pharmacokinetics and renal safety in primary TKA, and network meta-analysis of cellular orthobiologics versus hyaluronic acid in knee osteoarthritis.

Featured Knee Studies This Edition (October 2026)
Knee Reconstruction

1. A Preliminary, Three-Arm, Randomized, Double-Blinded, Placebo-Controlled Trial Comparing the Efficacy of Adductor Canal Pain Catheters Following Total Knee Arthroplasty

Authors: Wilke B, Sherman C, Ledford C, Heckman M, White L et al. | Journal: The Journal of the American Academy of Orthopaedic Surgeons (Oct 2026) | View Source / DOI

Situation

Optimal multimodal perioperative pain management after total knee arthroplasty (TKA) is critical to facilitate immediate mobilization while minimizing outpatient opioid consumption. This randomized, double-blinded, placebo-controlled trial evaluated whether indwelling adductor canal pain catheters provide superior analgesic or opioid-sparing efficacy compared with single-shot adductor canal blocks (ACB).

Background

While continuous adductor canal catheters have been advocated for extended postoperative sensory blockade without quadriceps motor inhibition, indwelling catheter maintenance poses logistical challenges, catheter displacement risks, and additional healthcare resource consumption.

Assessment & Findings
  • Study Design & Cohort: Prospective, randomized, double-blinded, placebo-controlled trial of 60 opioid-naive patients undergoing primary unilateral TKA randomized into three cohorts: (1) single-shot ACB with placebo saline catheter, (2) continuous ropivacaine infusion catheter, or (3) programmed intermittent bolus catheter, followed through 60 days postoperatively.
  • Opioid Consumption & Inpatient Pain: No statistically significant differences were observed across cohorts regarding inpatient oral morphine milligram equivalents (oMME), on-demand rescue analgesics, visual analog pain scores, or hospital length of stay (all P > 0.05).
  • Duration of Opioid Use: Although single-shot ACB patients exhibited a trend toward longer opioid usage duration (median 21 days vs 14 days in both catheter cohorts), this difference did not reach statistical significance (P = 0.59).
  • Patient-Reported Functional Recovery: Knee Injury and Osteoarthritis Outcome Score Junior (KOOS Jr) functional scores were identical among all three cohorts at both 30-day and 60-day postoperative evaluations (all P > 0.05).
Recommendation & Practice Takeaway

Clinical Pearl: Indwelling continuous or intermittent bolus adductor canal catheters do not confer meaningful analgesic advantages or functional acceleration over a properly executed single-shot adductor canal block combined with oral multimodal analgesia in opioid-naive TKA patients. Given the catheter-related management burden and potential dislodgement issues, surgeons and acute pain services should favor single-shot ACB for routine primary fast-track knee arthroplasty pathways.

Knee Reconstruction

2. Systemic Exposure and Renal Safety After Intrawound Vancomycin Powder in Primary Total Knee Arthroplasty: A Prospective Comparative Cohort Study

Authors: Bingol O, Karlidag T, Ozsoy H, Aydin T, Keskin O et al. | Journal: The Journal of Arthroplasty (Oct 2026) | View Source / DOI

Situation

Topical intrawound vancomycin powder application is increasingly utilized as local surgical site antimicrobial prophylaxis in joint arthroplasty. This prospective comparative study evaluated systemic pharmacokinetic absorption, nephrotoxicity profiles, and surgical site infection outcomes in primary TKA.

Background

Although topical vancomycin delivers high local intra-articular concentrations, clinical concerns persist regarding systemic absorption precipitating acute kidney injury (AKI) or chemical synovial irritation in primary joint replacement.

Assessment & Findings
  • Study Design & Cohort: Prospective comparative cohort study of 260 consecutive primary TKA patients at a tertiary academic center: 130 receiving 1.0 g intrawound vancomycin powder dusted into the joint prior to capsule closure and 130 matched controls without powder, monitored for KDIGO-defined AKI and 6-month infection outcomes.
  • Pharmacokinetics & Absorption: At 12 hours postoperatively, serum vancomycin levels remained undetectable (<1.00 mg/L) in 80.0% (104 of 130) of patients; the remaining 26 patients demonstrated negligible systemic concentrations (median 0.28 mg/L; range 0.01 to 2.76 mg/L), well below therapeutic trough thresholds. Serum levels did not correlate with creatinine or eGFR alterations (all P >= 0.720).
  • Renal Safety: KDIGO-defined acute kidney injury occurred in 6.9% (9 of 130) in the vancomycin cohort versus 6.2% (8 of 130) in controls (odds ratio 1.13; 95% CI, 0.42 to 3.04; P = 1.000), with all vancomycin group AKI episodes limited to transient Stage 1.
  • Infection Outcomes: No statistically significant differences were observed between cohorts in periprosthetic joint infection (PJI), superficial wound infection, or wound dehiscence rates.
Recommendation & Practice Takeaway

Clinical Pearl: Dosing 1 gram of intrawound vancomycin powder during primary TKA is pharmacokinetically safe with negligible systemic uptake and zero increased nephrotoxicity risk. However, because it confers no statistically significant reduction in PJI or wound dehiscence in standard-risk primary cases, routine universal application cannot be recommended. Restrict intrawound vancomycin powder prophylaxis to high-risk revisions, immunocompromised hosts, or operations with prolonged surgical duration.

Knee Reconstruction

3. Intra-articular Orthobiologics Show Statistically but Not Clinically Meaningful Improvements Compared With Viscosupplementation in Knee Osteoarthritis: A Network Meta-analysis of Randomized Controlled Trials

Authors: Han J, Jung M, Chung K, Moon H, Jung S et al. | Journal: Arthroscopy: The Journal of Arthroscopic and Related Surgery (Oct 2026) | View Source / DOI

Situation

Non-operative management of mild-to-moderate knee osteoarthritis (OA) frequently involves intra-articular injections. This network meta-analysis evaluated the comparative clinical efficacy and minimal clinically important difference (MCID) achievements of cellular and acellular orthobiologics versus hyaluronic acid (HA).

Background

While commercial marketing promotes platelet-rich plasma (PRP), stromal vascular fraction (SVF), bone marrow aspirate concentrate (BMAC), and umbilical cord mesenchymal stem cells (UC-MSC) as disease-modifying regenerative therapies, their true comparative superiority over conventional viscosupplementation remains hotly debated.

Assessment & Findings
  • Study Design & Cohort: Network meta-analysis of 24 randomized controlled trials encompassing 2,960 patients with symptomatic knee osteoarthritis comparing clinical outcomes across PRP, SVF, BMAC, UC-MSC, and hyaluronic acid through 12-month follow-up.
  • Pain & Functional Improvements: Although SVF and BMAC demonstrated statistically significant reductions in pain scores versus HA at 3, 6, and 12 months (mean difference -0.7 to -1.1) and functional score improvements (MD -0.6 to -1.4), neither pain nor functional score improvements exceeded established MCID thresholds.
  • Cumulative Ranking: At final follow-up, SUCRA rankings placed SVF highest, followed by BMAC and UC-MSC, with PRP intermediate and HA lowest; however, between-group differences remained clinically modest.
  • Structural & Safety Findings: MRI cartilage repair outcomes remained variable and inconsistent across studies. No serious adverse events were noted, though autologous harvesting procedures (bone marrow aspiration, liposuction) incurred donor-site pain.
Recommendation & Practice Takeaway

Clinical Pearl: Orthobiologic injections produce statistically measurable pain score reductions over hyaluronic acid, but the magnitude of improvement fails to reach minimal clinically important difference thresholds. Surgeons must ensure transparent patient counseling regarding the substantial out-of-pocket costs of stem cell and cellular orthobiologics, clarifying that symptom trajectories up to 12 months do not deliver dramatic clinical superiority or proven chondral regeneration over standard viscosupplementation.

Orthogate Weekly Journal Scan is curated and synthesized by ORION (Orthopaedic Research, Intelligence & Operations Navigator) for orthopaedic surgeons, fellows, and residents. Evidence synthesized under the clinical direction of Christian Veillette, MD, MSc, FRCSC.